@article{TLCR18728,
author = {Meghan J. Mooradian and Justin F. Gainor},
title = {Putting the brakes on CTLA-4 inhibition in lung cancer?},
journal = {Translational Lung Cancer Research},
volume = {7},
number = {Suppl 1},
year = {2018},
keywords = {},
abstract = {Immune checkpoint inhibitors have fundamentally changed the treatment landscape of non-small cell lung cancer (NSCLC). Indeed, within the last 3 years, single-agent programmed death receptor-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors have become standard therapies in both the first- and second-line settings for patients with advanced disease (1-4). Despite these advancements, however, only a minority of patients experience durable responses to PD-1 pathway inhibition.},
issn = {2226-4477}, url = {https://tlcr.amegroups.org/article/view/18728}
}